Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: Subgroup analyses from the phase 2b study

Multiple Sclerosis Journal

Volumn 18, Issue 3, 2012, Pages 314-321

  Kappos, Ludwig ^a   Gold, Ralf ^b   Miller, David H ^c   MacManus, David G ^c   Havrdova, Eva ^d   Limmroth, Volker ^e   Polman, Chris H ^f   Schmierer, Klaus ^c,g   Yousry, Tarek A ^c   Eraksoy, Mefkure ^h   Meluzinova, Eva ⁱ   Dufek, Michal ^j   Yang, Minhua ^k   Dawson, Kate ^k   O'Neill, Gilmore N ^k  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b ST JOSEF HOSPITAL   (Germany)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d CHARLES UNIVERSITY   (Czech Republic)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^h ISTANBUL UNIVERSITY   (Turkey)

ⁱ UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^j MASARYK UNIVERSITY   (Czech Republic)

^k BIOGEN   (United States)

more..

Author keywords

BG 12; demographics; disease modifying therapies; multiple sclerosis; relapsing remitting; subpopulation

Indexed keywords

FUMARIC ACID DIMETHYL ESTER; GADOLINIUM; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE DURATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

EID: 84863284276     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511421054     Document Type: Article

References (19)

1. Noseworthy J, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000 ; 343: 938-952
2. Sayre LM, Perry G, Smith MA. Oxidative stress and neurotoxicity. Chem Res Toxicol. 2008 ; 21: 172-188 (Pubitemid 351219718)
3. Qi X, Lewin AS, Sun L, Hauswirth WW, Guy J. Mitochondrial protein nitration primes neurodegeneration in experimental autoimmune encephalomyelitis. J Biol Chem. 2006 ; 281: 31950-31962 (Pubitemid 46041457)
4. Dawson VL, Dawson TM, Bartley DA, Uhl GR, Snyder SH. Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. J Neurosci. 1993 ; 13: 2651-2661 (Pubitemid 23151779)
5. Calabrese V, Ravagna A, Colombrita C, Scapagnini G, Guagliano E, Calvani M, et al. Acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress: involvement of the transcription factor Nrf2. J Neurosci Res. 2005 ; 79: 509-521 (Pubitemid 40283351)
6. Haorah J, Ramirez SH, Schall K, Smith D, Pandya R, Persidsky Y. Oxidative stress activates protein tyrosine kinase and matrix metalloproteinases leading to blood-brain barrier dysfunction. J Neurochem. 2007 ; 101: 566-576 (Pubitemid 46525283)
7. Lukashev M, Zeng W, Goelz D, Lee R, Linker R, Gold B, et al. Activation of Nrf2 and modulation of disease progression in EAE models by BG00012 (dimethyl fumarate) suggests a novel mechanism of action combining anti-inflammatory and neuroprotective modalities. Mult Scler. 2007 ; 13: S149
8. Wierinckx A, Brevé J, Mercier D, Schultzberg M, Drukarch B, van Dam AM. Detoxication enzyme inducers modify cytokine production in rat mixed glial cells. J Neuroimmunol. 2005 ; 166: 132-143 (Pubitemid 41074663)
9. Kappos L, Gold R, Miller DH, MacManus DG, Havrdova E, Limmroth V, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008 ; 372: 1463-1472
10. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol. 2001 ; 50: 121-127
11. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983 ; 33: 1444-1452 (Pubitemid 14237132)
12. Schimrigk S, Brune N, Hellwig K, Lukas C, Bellenberg B, Rieks M, et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol. 2006 ; 13: 604-610 (Pubitemid 43873632)
13. Scott TF, Schramke CJ, Novero J, Chieffe C. Short-term prognosis in early relapsing-remitting multiple sclerosis. Neurology. 2000 ; 55: 689-693
14. Losseff NA, Miller DH, Kidd D, Thompson AJ. The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis-preliminary results. Mult Scler. 2001 ; 7: 23-25 (Pubitemid 32396575)
15. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002 ; 346: 158-164 (Pubitemid 34438881)
16. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors of irreversible disability in multiple sclerosis: an amnesic process. Brain. 2003 ; 126: 770-782 (Pubitemid 36372978)
17. Macmanus DG, Miller DH, Kappos L, Gold R, Havrdova E, Limmroth V, et al. BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. J Neurol. 2011 ; 258: 449-456
18. Kappos L, Miller D, MacManus D, et al. The efficacy of BG00012 in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study. Neurology. 2008 ; 70 (Suppl. 1). A83
19. Kappos L, Miller DH, MacManus DG, et al. BG00012 reduces accumulation of gadolinium-enhancing lesions in subgroups of multiple sclerosis patients. Int J MS Care. 2008 ; 10 (Suppl. 1). 5